Abstract

The present invention relates to a dual structure-switching aptamer-mediated signal amplification cascade system for virus detection. The system, according to the present invention, has the advantages of having a simple virus detection procedure and enabling specific detection even within a short detection time of 30 minutes or less, thereby not requiring expensive enzymes and thermal control equipment. In addition, the system has the advantage of enabling the detection of an actual pathogen (especially a virus) at a level of 1.0 PFU.

IPC Classes  ?

• C12Q 1/682 - Signal amplification
• C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor

Abstract

3124511010) group.

IPC Classes  ?

• A01N 31/08 - Oxygen or sulfur directly attached to an aromatic ring system
• A01N 31/16 - Oxygen or sulfur directly attached to an aromatic ring system with two or more oxygen or sulfur atoms directly attached to the same aromatic ring system
• A01P 3/00 - Fungicides
• A01P 1/00 - DisinfectantsAntimicrobial compounds or mixtures thereof
• A61K 31/05 - Phenols
• A61P 31/04 - Antibacterial agents

Abstract

The present invention relates to a nanocomposite for cancer diagnosis and treatment, a composition comprising same for cancer treatment, and an ultrasonic contrast agent for cancer diagnosis and, more specifically, to a nanocomposite comprising at least one coordination nanoparticle for cancer diagnosis and treatment, a composition comprising same for cancer treatment, and a contrast agent for cancer diagnosis, wherein the coordination nanoparticle includes: a perfluorocarbon coordinating iron ions; at least one dopamine compound selected from the group consisting of dopamine and dopamine analogs; and a nucleophile.

IPC Classes  ?

• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61K 49/22 - Echographic preparationsUltrasound imaging preparations
• A61P 35/00 - Antineoplastic agents

Abstract

The present disclosure relates to novel cinnamamide derivatives and use thereof in preventing or treating cancer.

IPC Classes  ?

• A61K 31/4409 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
• A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents
• C07C 235/80 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms having carbon atoms of carboxamide groups and keto groups bound to the same carbon atom, e.g. acetoacetamides
• C07D 213/30 - Oxygen atoms

Abstract

The present invention relates to: a nucleic acid delivery complex comprising lipid nanoparticles; a composition comprising the nucleic acid delivery complex for delivering nucleic acids; and a nucleic acid delivery method comprising a step of treating, with the nucleic acid delivery complex, an object to which a nucleic acid is delivered.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61K 9/51 - Nanocapsules
• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle

Abstract

The present invention relates to a technology for detecting a target nucleic acid by using an argonaute protein and an artificial nucleic acid circuit. The system according to the present invention can specifically detect target pathogens added to a human sample with 100% clinical sensitivity without nucleic acid amplification and separate extraction steps, and can directly identify target pathogens collected from the surface of an object by using the system together with a three-dimensional nanopillar array structure. In addition, since a trigger sequence cleaved by an Ago protein is designed to be used as a guide, a single protein is used, and thus manufacturing is simpler than that of a conventional nucleic acid detection circuit, and cost are reduced in that target pathogens can be detected with high sensitivity even with trace amounts of target nucleic acid sequences as long as the Ago protein, a reporter, and a reporter complement according to the system of the present invention are not depleted. In addition, the system according to the present invention proceeds in a single step, and can be easily applied to the detection of various target nucleic acid sequences by appropriately changing a nucleic acid recognition site to match a target pathogen.

IPC Classes  ?

• C12Q 1/6818 - Hybridisation assays characterised by the detection means involving interaction of two or more labels, e.g. resonant energy transfer

Abstract

The present invention relates to a polymer composite comprising biomass, and a method for producing same, and, more specifically, to: a method for producing a polymer composite comprising Chlorella-derived biomass, the method comprising a saccharification step of performing acid-catalyzed saccharification on Chlorella biomass in the presence of an acid, a step of mixing the saccharification solution, obtained in the saccharification step, and calcium hydroxide so as to neutralize same, a step of recovering, from the neutralization product obtained in the neutralization step, a solid part containing a precipitated salt, and a step of mixing the solid part and a polymer so as to prepare a polymer mixture; and the polymer composite composite, which comprises: the solid part of a neutralized saccharification solution obtained after acid-catalyzed saccharification of Chlorella biomass and neutralization; and a polymer.

IPC Classes  ?

• C08K 5/1545 - Six-membered rings
• C08L 23/08 - Copolymers of ethene
• C08L 67/02 - Polyesters derived from dicarboxylic acids and dihydroxy compounds
• C08L 67/04 - Polyesters derived from hydroxy carboxylic acids, e.g. lactones

Abstract

The present invention relates to a novel histidine amide cholesterol compound and RNA delivery lipid nanoparticles comprising same. The present invention can have improved mRNA delivery efficiency and expression efficiency while having biocompatibility.

IPC Classes  ?

• C07J 43/00 - Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta[a]hydrophenanthrene skeleton
• A61K 9/51 - Nanocapsules
• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present invention relates to a method for improving muscle strength, and/or muscle mass by administering a composition containing as an active ingredient at least one selected from the group consisting of Akkermansia muciniphila cells, a culture thereof and a lysate thereof, and a method for preventing or treating muscle diseases where muscle strength and/or mass is weakened by sarcopenia, cachexia or muscle wasting.

IPC Classes  ?

• A61K 35/741 - Probiotics
• A61K 35/00 - Medicinal preparations containing materials or reaction products thereof with undetermined constitution
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system

Abstract

The present invention relates to a novel benzofuran compound and a pharmaceutical composition comprising same for preventing or treating cancer. The compound according to the present invention or a pharmaceutically acceptable salt thereof binds to hnRNPA2B1 to inhibit the translation of HIF-1α, thus exhibiting an excellent prophylactic and therapeutic effect on cancer diseases of various carcinomas. In particular, the present invention exhibits an effect of having excellent anticancer activity through the effect of inhibiting cancer metastasis as well as the effect of inhibiting cell death.

IPC Classes  ?

• C07D 493/04 - Ortho-condensed systems
• A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
• A61P 35/00 - Antineoplastic agents
• A61P 35/04 - Antineoplastic agents specific for metastasis

Abstract

e.g.e.g., a fluorescent signal). In some aspects, such methods are useful for diagnosing and treating a subject such as a subject having a cancer.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12N 9/22 - Ribonucleases
• C12Q 1/6823 - Release of bound markers

Abstract

The present invention relates to a novel antibody specifically binding to GPC3 or an antigen-binding fragment thereof, a chimeric antigen receptor comprising an antigen-binding variable fragment of the antibody, and immune cells expressing the chimeric antigen receptor.

IPC Classes  ?

• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• C07K 14/725 - T-cell receptors
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61P 35/00 - Antineoplastic agents
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present invention relates to an antibody or an antigen-binding fragment thereof, which specifically binds to TM4SF5 and can thus be effectively used for preventing, treating, and diagnosing diseases caused by the overexpression of TM4SF5.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 31/4412 - Non-condensed pyridinesHydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present disclosure relates to a dual enzyme amplification-based colorimetric sensor system for on-site detection of pathogens. The colorimetric sensor system according to the present disclosure may comprise a combination of the CRISPR/Cas12a system with an enzymatic reaction of urease, thereby facilitating on-site detection of pathogens without separate analytical equipment by analyzing the color change through dual enzyme amplification. In addition, it is possible to selectively change the target by changing the crRNA sequence depending on the target pathogen to be detected, which has the advantage of being applicable to various types of pathogens without limitation. Further, the present disclosure can be used as a point of care service (PoC) system capable of detecting the genes of pathogens directly down to the sub-ng level without separate analysis equipment by applying the detection color value derived using the colorimetric sensor system according to the present disclosure to a smartphone application (app).

IPC Classes  ?

• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
• C12N 9/22 - Ribonucleases
• C12Q 1/44 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase involving esterase
• G01N 33/52 - Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper
• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

The present invention relates to a transformed human hepatic stellate cell line, and a use thereof. The hepatic stellate cell line according to the present invention exhibits an improvement in drug response, and when co-cultured with hepatic stellate cells, does not exhibit a functional decrease in the hepatic cells, and thus can be advantageously used in an in vitro culture model.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The present invention relates to an mRNA structure platform capable of expressing a protein with high efficiency.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides

Abstract

The present invention relates to: a transformed strain expressing and secreting Akkermansia muciniphila TARS (AmTARS); and a vector for producing same. More specifically, the present invention relates to an Escherichia coli Nissle 1917 (EcN) strain expressing AmTARS, a composition comprising same, a novel vector for producing same, and an EcN transformation method using same.

IPC Classes  ?

• A61K 35/74 - Bacteria
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

The present invention relates to a single domain antibody against Serpin A12 and a use thereof. The antibody according to the present invention is a single domain antibody against Serpin A12, which has high affinity for Serpin A12 through high affinity, thereby exhibiting excellent therapeutic efficacy for bone diseases.

IPC Classes  ?

• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• A61P 19/00 - Drugs for skeletal disorders
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present invention relates to a pharmaceutical composition for the prevention or treatment of nontuberculous mycobacteria infection. A CD36 inhibitor, sulfo-N-succinimidyl oleate (SSO), and SSO derivatives, according to an aspect of the present invention, have the effect of inhibiting the growth, proliferation and the like of nontuberculous mycobacteria, and thus can be effectively used in the prevention or treatment of nontuberculous mycobacteria infection or nontuberculous mycobacteria pulmonary disease.

IPC Classes  ?

• C07D 207/28 - 2-Pyrrolidone-5- carboxylic acidsFunctional derivatives thereof, e.g. esters, nitriles
• A61K 31/4015 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
• A61K 31/421 - 1,3-Oxazoles, e.g. pemoline, trimethadione
• A61P 31/04 - Antibacterial agents
• A61P 11/00 - Drugs for disorders of the respiratory system
• C07D 263/26 - Oxygen atoms attached in position 2 with hetero atoms or acyl radicals directly attached to the ring nitrogen atom
• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives

Abstract

The present invention relates to a fluorescent protein variant for observing cell damage, a gene encoding same, a vector system comprising same and a transgenic cell using same, and uses thereof. It is possible to monitor cell damage in real time of the transgenic cell as the fluorescence expression level that changes depending on the activity of caspase 3 or caspase 7 can be confirmed in real time. Furthermore, the transgenic cell according to the present invention may be used to evaluate the toxicity of various drugs. Accordingly, the present invention can be effectively used in cell damage research or drug development.

IPC Classes  ?

• C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• C12N 9/64 - Proteinases derived from animal tissue, e.g. rennin
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances

Abstract

The present invention relates to: a microalgae strain with restricted pigment biosynthesis; a method for producing useful substances from same; and a composition comprising the useful substances. The present invention relates to: a microalgae strain with restricted pigment production; a method for producing useful substances derived from the microalgae strain, comprising the steps of culturing the microalgae strain to obtain a culture which is biomass, a culture medium, or a mixture thereof, and obtaining useful substances by separating the useful substances from residues through extraction from the obtained culture, wherein the extracted extract has a white or transparent color; a cosmetic composition containing, in an oil phase part, an oil component extracted from a culture which is biomass of the microalgae strain of the present invention, a culture medium, or a mixture thereof; an artificial meat containing amino acid, protein, or a mixture thereof; and a biodegradable plastic material containing a degreased residue remaining after extracting lipids from the culture which is biomass, a culture medium, or a mixture thereof, or dried biomass of the strain.

IPC Classes  ?

• C12N 1/12 - Unicellular algaeCulture media therefor
• A61K 8/9722 - Chlorophycota or Chlorophyta [green algae], e.g. Chlorella
• A23L 29/00 - Foods or foodstuffs containing additivesPreparation or treatment thereof
• C12P 1/00 - Preparation of compounds or compositions, not provided for in groups , by using microorganisms or enzymesGeneral processes for the preparation of compounds or compositions by using microorganisms or enzymes
• C12R 1/89 - Algae

Abstract

The present invention relates to a promoter for gene expression in retinal cells, and a vector system comprising same. The promoter for gene expression in retinal cells and the vector system including same according to the present invention have a minimal unit for promoter activity and, unlike existing known promoters in retinal cells, maintain a high level of expression of a target gene, and thus can be used to maximize the expression of the target protein in retinal cells.

IPC Classes  ?

• C12N 15/86 - Viral vectors
• C12N 5/0793 - Neurons

Abstract

The present disclosure relates to a cell-penetrating peptide, an anticancer peptide, and a pharmaceutical composition for preventing or treating cancer including the same. The cell-penetrating peptide of the present disclosure can further improve a cancer cell growth inhibitory effect of anticancer peptides, especially cancer therapeutic peptides with improved anticancer activity by cyclic structures, and thus can be effectively applied to the prevention or treatment of various cancers.

IPC Classes  ?

• C07K 7/64 - Cyclic peptides containing only normal peptide links
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 35/00 - Antineoplastic agents
• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids

Abstract

The present invention relates to: a novel chimeric antigen receptor containing, as an intracellular signaling domain, an intracellular domain of a receptor containing a dead region; and immune cells expressing the chimeric antigen receptor. In environments in which normal cells are present, the immune cells expressing the chimeric antigen receptor according to the present invention exhibit little or no cytotoxicity and cell death of the immune cells is exhibited, thus ensuring the stability of the normal cells. Conversely, in environments in which target cells are present, the immune cells exhibit more potent cytotoxicity than with conventional techniques utilizing a lone chimeric antigen receptor.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C07K 14/725 - T-cell receptors
• C07K 14/73 - CD4
• C07K 14/735 - Fc receptors
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells

Abstract

The present invention relates to two types of novel Bifidobacterium animalis subspecies lactis strains, a Lactobacillus paracasei strain, a Lactobacillus gasseri strain, or a combination thereof and uses thereof. The strains increase mitochondrial synthesis by increasing the activity of AMP-activated protein kinase (AMPK) protein present in muscle cells, thereby improving the ability of muscles to perform exercise, and thus can be used for the improvement of muscle function or can be effectively used as a medicine, a health functional food, or a food, for the prevention, amelioration or treatment of muscle diseases.

IPC Classes  ?

• C12N 1/20 - BacteriaCulture media therefor
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A61K 35/745 - Bifidobacteria
• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• C12R 1/01 - Bacteria or actinomycetales
• C12R 1/225 - Lactobacillus

Abstract

The present invention relates to a novel enzyme capable of producing multi-hydroxy derivatives from polyunsaturated fatty acids and a method for producing multi-hydroxy derivatives of polyunsaturated fatty acids using the same.

IPC Classes  ?

• C12P 7/6427 - Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
• A61P 35/00 - Antineoplastic agents
• C11C 3/00 - Fats, oils or fatty acids obtained by chemical modification of fats, oils or fatty acids, e.g. by ozonolysis
• C12N 9/02 - Oxidoreductases (1.), e.g. luciferase
• C12P 7/6432 - Eicosapentaenoic acids [EPA]
• C12P 7/6434 - Docosahexenoic acids [DHA]
• C12P 17/02 - Oxygen as only ring hetero atoms

Abstract

The present invention relates to a cell culture substrate and a method for culturing stem cells using same, wherein the cell culture substrate has a polymer thin film deposited thereon for stem cell cultivation, which can replace animal-derived materials that are essential in pluripotent stem cell culture. According to the present invention, human pluripotent stem cells, which are conventionally cultured using animal-derived feeder cells or Matrigel, can also be cultured on a cell culture vessel that is coated with a polymer thin film and excludes animal-derived materials, whereby safer stem cell therapeutics can be produced.

IPC Classes  ?

• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• C12N 5/0735 - Embryonic stem cellsEmbryonic germ cells
• C12N 5/074 - Adult stem cells

Abstract

The present invention relates to a method for preparing directly reprogrammed natural killer (drNK) cells or CAR (chimeric antigen receptor) gene introduced CAR-drNK cells using substances and methods that inhibit BCL11B (B-cell leukemia 11B) gene expression and/or function. The present invention also relates to drNK cells or CAR-drNK cells prepared by a BCL11B gene-based cell reprogramming method, and a cell therapeutic and/or a composition for the prevention or treatment of cancer diseases and infectious diseases caused by viruses, bacteria, fungi, and the like, and/or inflammatory diseases, which contain the cells.

IPC Classes  ?

• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C07K 14/725 - T-cell receptors
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• C12N 9/22 - Ribonucleases
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/90 - Stable introduction of foreign DNA into chromosome

Abstract

A composition according to the present invention not only improves sleep or maintains sound sleep but also restores the balance of intestinal microorganisms disrupted by sleep disorders, and thus can help in managing health conditions such as metabolic syndrome.

IPC Classes  ?

• A61K 35/744 - Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
• A61P 25/20 - HypnoticsSedatives
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics

Abstract

The present invention relates to a novel Bifidobacterium longum ssp. infantis strain and use thereof.

IPC Classes  ?

• C12N 1/20 - BacteriaCulture media therefor
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A61K 35/745 - Bifidobacteria
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• C12R 1/01 - Bacteria or actinomycetales

Abstract

The present invention relates to a novel Lactobacillus sp. strain and a use thereof.

IPC Classes  ?

• C12N 1/20 - BacteriaCulture media therefor
• C12R 1/225 - Lactobacillus

Abstract

The present invention relates to a therapeutic agent of a lipase inhibitor for a wide spectrum of RNA viral infections in humans and animals. More specifically, the lipase inhibitor can be used as a therapeutic agent for influenza A virus infection, bovine coronavirus infection, porcine epidemic diarrhea coronavirus infection, bovine rotavirus infection, porcine reproductive and respiratory syndrome virus infection, and sapoviral infection and furthermore, can be utilized as a therapeutic agent for various RNA viral infections in humans and animals, such as infections with SARS COV-1, MERS-COV, Zika virus, dengue fever virus, and hepatitis A and C viruses.

IPC Classes  ?

• A61K 31/17 - Amides, e.g. hydroxamic acids having the group N—C(O)—N or N—C(S)—N, e.g. urea, thiourea, carmustine
• A61K 31/215 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
• A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• A61P 31/14 - Antivirals for RNA viruses
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses

Abstract

The present invention relates to a composition containing extracts from Garcinia cambogia and Acanthopanax for prevention or treatment of liver diseases and, more specifically, to a composition for prevention or treatment of liver disease, the composition containing, as active ingredients, (i) a Garcinia cambogia extract, hydroxycitric acid (HCA), or a derivative of hydroxycitric acid; and (ii) an Acanthopanax extract, Chiisanogenin, or a derivative of Chiisanogenin.

IPC Classes  ?

• A61K 36/254 - Acanthopanax or Eleutherococcus
• A61K 31/191 - Acyclic acids having two or more hydroxy groups, e.g. gluconic acid
• A61K 31/365 - Lactones
• A61K 36/38 - Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Abstract

The present invention relates to an indole compound derivative that decomposes IKZF2 and a use thereof. More specifically, a compound of chemical formula 1 provides an agent having a novel mechanism of action against the IKZF2 protein, and thus is useful for the treatment of diseases and disorders related to the IKZF2 protein, and can in particular be effectively used for preventing or treating cancer.

IPC Classes  ?

• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61P 35/00 - Antineoplastic agents
• C07D 471/04 - Ortho-condensed systems

Abstract

The present invention relates to novel strains having anti-Helicobacter pylori activity and uses thereof.

IPC Classes  ?

• C12N 1/20 - BacteriaCulture media therefor
• A01N 63/20 - BacteriaSubstances produced thereby or obtained therefrom
• A01P 1/00 - DisinfectantsAntimicrobial compounds or mixtures thereof
• A61K 35/74 - Bacteria
• A61P 31/04 - Antibacterial agents
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• C12R 1/25 - Lactobacillus plantarum
• C12R 1/225 - Lactobacillus
• C12R 1/01 - Bacteria or actinomycetales

Abstract

The present invention relates to a pharmaceutical composition, health functional food composition or health functional food for the prevention, treatment or amelioration of sarcopenia, comprising at least one of one or more short-chain or medium-chain fatty acids, ester(s) thereof, or triglyceride form(s) thereof. Also, the present invention relates to a composition for the diagnosis of a possible sarcopenia group or a sarcopenia group, the composition comprising, as an active ingredient, an agent for measuring the content of one or more short-chain or medium-chain fatty acids in the blood, and relates to a method for providing information for determining a possible sarcopenia group or a sarcopenia group, the method comprising a step of measuring the content of one or more short-chain or medium-chain fatty acids from the blood of a subject.

IPC Classes  ?

• A61K 31/19 - Carboxylic acids, e.g. valproic acid
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A23L 33/12 - Fatty acids or derivatives thereof
• G01N 30/72 - Mass spectrometers
• G01N 30/88 - Integrated analysis systems specially adapted therefor, not covered by a single one of groups

Abstract

The present invention relates to a novel compound isolated from spinach, and a composition comprising same for preventing or treating inflammatory diseases, and, more particularly, to a novel medicagenic acid glycoside compound isolated from spinach, a preparation method therefor, and a composition comprising same for preventing or treating inflammatory diseases.

IPC Classes  ?

• C07H 15/256 - Polyterpene radicals
• A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
• A61K 36/21 - Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
• A61P 11/06 - Antiasthmatics
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• C07H 1/08 - SeparationPurification from natural products

Abstract

The present invention relates to: a method for converting non-pluripotent cells into pluripotent cells; cells produced by the method; and uses thereof. The pluripotent cells of the present invention have low tumorigenicity while having excellent cell differentiation ability and pluripotency capable of differentiating into three germ layers, and can specifically separate pluripotent cells in the intermediate stage of reprogramming, and thus, it is possible to produce pluripotent cells having characteristics different from conventional induced pluripotent stem cells.

IPC Classes  ?

• A61K 35/545 - Embryonic stem cellsPluripotent stem cellsInduced pluripotent stem cellsUncharacterised stem cells
• A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
• C12N 5/074 - Adult stem cells

Abstract

The present invention relates to stem cells with suppressed FTO gene expression, immune cells differentiated therefrom, and uses thereof. In the present invention, it was found that suppressing the expression of the FTO gene in immune cells significantly improves cytolytic activity and that the immune cells differentiated from the stem cells with FTO gene expression suppressed therein exhibited superior cytolytic activity against cancer cells, whereby the limitations of existing immune cell therapies, such as immune mismatch and limited cell numbers, were overcome. Furthermore, in the present invention, the CAR gene was introduced into the location of the FTO gene in stem cells to generate stem cells that delete the FTO gene while expressing the CAR gene. The immune cells differentiated from the stem cells demonstrated significantly superior cytolytic activity against cancer cells. Therefore, the present invention can be effectively utilized as an immune anticancer cell therapy.

IPC Classes  ?

• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to a complex for bioimaging, diagnosis, and treatment of cancer cells. The complex of the present invention comprises fluorescent nanoparticles and a manganese salt conjugated to the surface of the fluorescent nanoparticles, and the fluorescence of the fluorescent nanoparticles in the complex is quenched due to the conjugation of the manganese salt.

IPC Classes  ?

• A61K 49/00 - Preparations for testing in vivo
• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61P 35/00 - Antineoplastic agents
• B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• B82Y 20/00 - Nanooptics, e.g. quantum optics or photonic crystals

Abstract

Provided is a composition for the prevention or treatment of Hutchinson-Gilford Progeria syndrome (HGPS) using gene editing, which contains sgRNA that hybridizes to mRNA encoding progerin, which causes HGPS, and a gene encoding Cas13 protein acting on the same. When introduced into the cell of a subject to be treated and only the mRNA encoding progerin is selectively cut. There is no need for co-prescribing with other therapies and fewer side effects occur than traditional farnesyltransferase inhibitors (FTIs). The efficiency is higher than when treated using homologous recombination (HR) at the DNA level, treatment using composition can be made reversibly, and the composition can be applied specifically compared to targeted treatment using RNAi (RNA interference), and has fewer side effects. Compared to treatment using CRISPR/Cas9, which directly acts on DNA and produces irreversible results, treatment using composition is reversible and selectively cut only mRNA encoding progerin, thereby ensuring safety.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61K 38/46 - Hydrolases (3)
• A61P 39/00 - General protective or antinoxious agents
• C12N 9/22 - Ribonucleases
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof

Abstract

An NK cell cytotoxicity prediction method of the present invention can predict the cytotoxicity of NK cells with respect to cancer cells according to ligand expression levels by analyzing active or inhibitory ligands that contribute highly to the toxicity of NK cells, thereby also predicting the activity of immune cells used in anticancer cell treatment, in addition to the activity of NK cells in various cancer types, and thus can be effectively used as a tool for patient-specific anticancer treatment. In addition, the CAR-NK cell cytotoxicity prediction method of the present invention can predict the cytotoxicity of CAR-NK cells with respect to cancer cells according to the expression levels of ligands expressed on the surface of cancer cells and target antigens of CAR.

IPC Classes  ?

• G16B 40/20 - Supervised data analysis
• G16B 25/00 - ICT specially adapted for hybridisationICT specially adapted for gene or protein expression
• G16B 45/00 - ICT specially adapted for bioinformatics-related data visualisation, e.g. displaying of maps or networks
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells

Abstract

The present invention provides an impedance-based organoid evaluation system comprising an organoid deformation generating unit including a first tube and a plurality of second tubes having a diameter smaller than that of the first tube, connected to one end of the first tube or inserted therein; and an impedance measuring unit connected to the organoid deformation generating unit and including an impedance analyzer for measuring the impedance of the organoid, and evaluating the organoid from the impedance measured by the impedance measuring unit.

IPC Classes  ?

• G01N 27/04 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance by investigating resistance
• C12M 1/26 - Inoculator or sampler
• C12M 1/34 - Measuring or testing with condition measuring or sensing means, e.g. colony counters
• G01N 33/483 - Physical analysis of biological material

Abstract

The present invention relates to a CD5 antibody and a chimeric antigen receptor (CAR) including the same. The chimeric antigen receptor of the present invention may be expressed in an immune cell to be utilized for an immuno-oncology therapy having reduced toxicity against a normal T cell.

IPC Classes  ?

• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/02 - Antineoplastic agents specific for leukemia
• C07K 14/725 - T-cell receptors
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12N 15/86 - Viral vectors

Abstract

The present invention relates to novel peptides having anti-inflammatory and tissue regenerative actions and uses thereof.

IPC Classes  ?

• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 17/00 - Drugs for dermatological disorders
• A61P 17/14 - Drugs for dermatological disorders for baldness or alopecia
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/22 - Anxiolytics
• A61P 25/24 - Antidepressants
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

The present invention relates to a novel signal sequence peptide and a vector comprising a polynucleotide encoding same. The signal sequence peptide can induce a protein linked thereto to be secreted to the outside of a cell, and thus, when the signal sequence peptide is used or a recombinant microorganism transformed with the vector is used, the signal sequence peptide expresses a target protein and then secretes the target protein to the outside of a cell, thus enabling the target protein to exhibit the activity and function thereof.

IPC Classes  ?

• C07K 14/195 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria
• C12N 15/70 - Vectors or expression systems specially adapted for E. coli
• C12N 15/74 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora

Abstract

2-62-6 aminoalcohol and a vegetable oil containing neutral fats, which provide at least two types of fatty acids through hydrolysis.

IPC Classes  ?

• C12P 17/06 - Oxygen as only ring hetero atoms containing a six-membered hetero ring, e.g. fluorescein
• C12P 7/04 - Preparation of oxygen-containing organic compounds containing a hydroxy group acyclic
• C12P 13/02 - Amides, e.g. chloramphenicol
• A61K 8/42 - Amides
• A61Q 19/00 - Preparations for care of the skin
• A23K 20/10 - Organic substances
• A61K 31/164 - Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
• A61P 35/00 - Antineoplastic agents
• A61K 36/28 - Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives

Abstract

The present invention relates to a target for stably forming immunological synapses and improving cytolytic activity in immune cells, and use thereof, and uses an inhibitor of NgR1 protein activity or expression, and thus can improve the stability of synapse formation and can improve cytolytic activity or cytotoxicity, and uses the NgR1 protein as a target so as to measure activity or expression level, and thus can screen for novel anticancer agents. In addition, the present invention can promote the formation of immunological synapses, which are points of contact between immune cells and cancer cells, and can also regulate, in organs and tissue in the body, cell-to-cell contact between various cells that are the same or different from each other, including immune cells, cancer cells, nerve cells and the like, and thus can regulate cell functions.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The present invention provides a compound represented by chemical formula 1, an optical isomer thereof or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition for preventing or treating Wnt/β-catenin signaling-associated diseases, comprising same.

IPC Classes  ?

• C07K 7/56 - Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61P 19/08 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
• C12N 1/20 - BacteriaCulture media therefor
• A61K 38/00 - Medicinal preparations containing peptides
• C12R 1/465 - Streptomyces

Abstract

The present invention relates to a culture method for non-xenogeneic culturing of intestinal stem cells on a culture dish coated with a polymeric thin film, which does not include xenogeneic components such as Matrigel, and a use thereof. The method for culturing intestinal stem cells according to the present invention enables easy and rapid cultivation of homogeneous cells, enables mass-cultivation of cells at a low cost, and eliminates the risk of xenogeneic infection by culturing cells in a non-xenogeneic culture environment, thereby enabling the development of cell therapeutics that can actually be transplanted in practice. Another advantage is that cells can be cultured in a state in which cellular characteristics are maintained even during organ subculture and cryopreservation. Furthermore, the method for producing intestinal epithelial cells, according to the present invention, enables intestinal organoid-derived intestinal stem cells cultured in a non-xenogeneic culture environment to differentiate into intestinal epithelial cells in the same non-xenogeneic culture environment.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor

Abstract

The present invention relates to a composition for preventing or treating cancer, comprising a dual expression vector, and more specifically, to a method for effectively treating cancer by simultaneously inducing the actions of cancer metabolism drugs and cancer immunotherapy drugs by using a dual expression vector for simultaneously expressing an HIF-1α inhibitor and anticancer cytokines.

IPC Classes  ?

• A61K 38/44 - Oxidoreductases (1)
• A61K 38/19 - CytokinesLymphokinesInterferons
• A61K 38/20 - Interleukins
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to a novel lipid compound and a lipid nanoparticle (LNP) composition containing same. The lipid compound according to the present invention can either directly or indirectly bind to and surround an active substance through multivalent interactions, thereby increasing the structural stability of the active substance. In addition, when administered in vivo, the lipid nanoparticle composition containing the lipid compound significantly enhances the delivery efficiency into cells and the activity of the active substance, and thus can be useful for the treatment and prevention of diseases.

IPC Classes  ?

• C07C 275/32 - Derivatives of urea, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
• C07C 335/08 - Derivatives of thiourea having nitrogen atoms of thiourea groups bound to acyclic carbon atoms of a saturated carbon skeleton
• C07D 207/337 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• C07D 233/90 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• C07D 209/18 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• C07D 239/52 - Two oxygen atoms
• C07D 473/34 - Nitrogen atom attached in position 6, e.g. adenine
• C07D 473/30 - Oxygen atom attached in position 6, e.g. hypoxanthine
• C07D 239/47 - One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
• A61K 9/51 - Nanocapsules

Abstract

One aspect relates to a method which finds an index gene in the same genome as DEG and performs DEG-index-ratio (Dir) transformation using the index gene, so that RNA-seq data can be used to provide information for diagnosis of a disease. The method, according to one aspect, can control individual data variations in RNA-seq results through multidimensional Dir transformation and can be useful in providing information for early diagnosis of a disease.

IPC Classes  ?

• G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
• G16B 30/10 - Sequence alignmentHomology search
• G16B 50/00 - ICT programming tools or database systems specially adapted for bioinformatics

Abstract

3232322); and a bio-sensor including the MXene transistor.

IPC Classes  ?

• G01N 27/414 - Ion-sensitive or chemical field-effect transistors, i.e. ISFETS or CHEMFETS
• B82Y 15/00 - Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors

Abstract

The present invention relates to an antimicrobial adjuvant containing a biphenyl derivative compound as an active ingredient, and a technology of various uses thereof. The compound of the present invention reduces the dosage of polymyxin antibiotics, which are administered to inhibit the proliferation of gram-negative bacteria, by enhancing the sensitivity of the gram-negative bacteria with respect to the polymyxin antibiotics, is concomitantly administered with the polymyxin antibiotics to show gram-negative bacteria growth inhibitory and killing effects, may notably reduce side effects such as nephrotoxicity, and may prevent or treat sepsis and septic shock due to antibiotic overuse.

IPC Classes  ?

• A61K 31/06 - Phenols the aromatic ring being substituted by nitro groups
• A61K 38/12 - Cyclic peptides
• A61P 31/04 - Antibacterial agents

Abstract

The present invention relates to a YaxAB nanopore, a system comprising the nanopore and applications thereof. The YaxAB nanopore of the present invention has a funnel-shaped three-dimensional structure so that a change in current blocking according to movement of an analyte captured inside the nanopore can be maximized to enable very sensitive measurements of even the structure of the analyte and minute physical and chemical characteristic changes including dynamic change and the like, and can cause very strong electroosmosis with high cation selectivity such that various types of analytes can be captured and analyzed without limiting the types of overall charges. Additionally, with respect to the nanopore of the present invention, the amino acid sequence of a monomer constituting the nanopore can be adjusted to improve protein purification yield and control oligomerization mechanism, and thus a YaxAB nanopore having a pore size that cannot be formed by a wild-type monomer can be prepared. Furthermore, with respect to the nanopore of the present invention, YaxAB nanopores of various pore sizes can be ensured using one-time purification, and a nanopore of a desired pore size can be selectively ensured. Therefore, limitations of a conventional biological nanopore with a fixed pore size can be overcome such that, with respect to the YaxAB nanopore of the present invention, the size of a nanopore can be adjusted according to the size of an analyte. Additionally, the YaxAB nanopore of the present invention has analyte analysis spectrums of a very wide dynamic range of detection from a small analyte up to a large analyte, resulting from the funnel-shaped three-dimensional structure with a wide inlet and a narrow outlet. Moreover, the YaxAB nanopore of the present invention has the largest nanopore structure among biological nanopores up to now, and large-sized analytes that cannot be detected by conventional biological nanopores can undergo single molecule detection and analysis on the basis of a funnel structure with a large inlet. In addition, the present invention has established an optimized composition of a membrane in which the YaxAB nanopore can exist stably, and, by using a sensor implemented on the basis thereof, various types of analytes having relatively various sizes and charges can be qualitatively and quantitatively analyzed at a single molecular level with very high resolution and sensitivity.

IPC Classes  ?

• G01N 33/487 - Physical analysis of biological material of liquid biological material
• C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof

Abstract

The present invention relates to a vector that operates in strains of the Bacteroides genus, which are beneficial gut microbes. The vector carries the nucleic acid sequence of SEQ ID NO: 1 necessary for the transformation of Escherichia coli and Bacteroides strains, and the nucleic acid sequence of SEQ ID NO: 2 including the origin of replication for Bacteroides strains. By recombining the nucleic acid sequence of SEQ ID NO: 2 with that of SEQ ID NO: 1, the vector can stably exist and autonomously replicate within Bacteroides strains to maintain a high number of copies. Thus, the vector can be advantageously used as a gut biosensor or for manufacturing tool for microbiome-based therapeutic agents in the future.

IPC Classes  ?

• C12N 15/74 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
• C12N 15/70 - Vectors or expression systems specially adapted for E. coli

Abstract

The present invention relates to a localized surface plasmon resonance (LSPR) sensor and a manufacturing method therefor, wherein the LSPR comprises a metal nanostructure layer, a graphene layer formed on the metal nanostructure layer and in contact with the metal nanostructure layer, electrodes formed at both ends of the graphene layer, and a receptor, disposed on the top of the graphene layer, specific for a detection target substance.

IPC Classes  ?

• G01N 21/552 - Attenuated total reflection
• G01N 21/25 - ColourSpectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
• G01N 21/59 - Transmissivity
• B82Y 15/00 - Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
• B82Y 20/00 - Nanooptics, e.g. quantum optics or photonic crystals
• B82Y 40/00 - Manufacture or treatment of nanostructures

Abstract

The present invention relates to mature intestinal organoid-derived mesenchymal stromal cells, and a use thereof. The mature intestinal organoid-derived mesenchymal stromal cells according to the present invention can act directly on a lesion site to significantly enhance regeneration and engraftment efficacy, and thus can significantly enhance the efficiency of transplantation. Further, the mature intestinal organoid-derived mesenchymal stromal cells according to the present invention have excellent efficacy due to being capable of regenerating damaged regions immediately and directly, unlike conventional mesenchymal stem cell therapeutic agents, allow for the application of a simplified subculture method, can maintain the characteristics thereof even when frozen and thawed, and can be utilized in allogeneic transplantation, thus having the advantage of a high likelihood of universal applicability.

IPC Classes  ?

• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• A61K 35/38 - StomachIntestineGoblet cellsOral mucosaSaliva
• A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Abstract

Citri tangerinae SemenCitri tangerinae Semen extract; and use thereof. The Citri tangerinae Semen extract of the present invention inhibits, in vivo, inflammatory responses caused by particulate matter or endotoxin contained in particulate matter, and increased expression of cell adhesion molecules, and thus can be applied to the prevention, amelioration or treatment of diseases caused by particulate matter or endotoxin contained in particulate matter.

IPC Classes  ?

• A61K 36/752 - Citrus, e.g. lime, orange or lemon
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A23K 10/30 - Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hayAnimal feeding-stuffs from material of fungal origin, e.g. mushrooms

Abstract

The present invention relates to a high-performance mature human intestinal organoid regenerative therapeutic agent derived from pluripotent stem cells. The high-performance mature human intestinal organoid regenerative therapeutic agent derived from pluripotent stem cells according to the present invention includes peristromal cell layers containing mesenchymal stromal cells, derived from the intestine, as the microenvironment around the intestine. That is, the high-performance mature human intestinal organoid regenerative therapeutic agent derived from pluripotent stem cells according to the present invention can exhibit high engraftment ability when transplanted together with peripheral cell layers around intestinal organoids and can exhibit superior regenerative ability through intestinal stem cells present in mature intestinal organoids, and therefore is likely to be useful as a regenerative therapeutic agent.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
• A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• A61K 35/38 - StomachIntestineGoblet cellsOral mucosaSaliva
• A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Abstract

The present invention relates to a novel antibody or an antigen-binding fragment thereof, which specifically binds to PD-L1, a chimeric antigen receptor comprising an antigen-binding variable fragment of the antibody, immune cells expressing the chimeric antigen receptor, and a pharmaceutical composition for treating or preventing cancer, the pharmaceutical composition comprising the immune cells.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 14/725 - T-cell receptors
• A61P 35/00 - Antineoplastic agents
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes

Abstract

The present invention relates to a novel Eutreptiella sp. strain and a method for producing fatty acids by using same and, more specifically, to: an Eutreptiella sp. strain having the ability to produce fatty acids; and a method for producing fatty acids, the method comprising a step of culturing an Eutreptiella sp. strain and a step of extracting fatty acids from the strain.

IPC Classes  ?

• C12N 1/10 - ProtozoaCulture media therefor
• C12P 7/6409 - Fatty acids
• C12R 1/90 - Protozoa

Abstract

The present invention provides: compounds having a specific chemical structure and having the activity of inhibiting or decomposing CDK2 and/or CDK9, or pharmaceutically acceptable salts thereof; and a method for preparing same. The present invention provides a composition comprising the compounds or pharmaceutically acceptable salts thereof. The present invention provides: a use of the compounds, salts thereof, and composition comprising same according to the present invention for inhibiting or decomposing CDK2 and/or CDK9; and medicinal uses for preventing or treating diseases associated with same. The present invention also provides a method for preventing or treating CDK2 and/or CDK9-related diseases, the method comprising administering, to an individual in need of treatment, an effective amount of the compounds, salts thereof, or composition comprising same according to the present invention.

IPC Classes  ?

• C07D 473/34 - Nitrogen atom attached in position 6, e.g. adenine
• A61K 31/52 - Purines, e.g. adenine
• A61P 35/00 - Antineoplastic agents
• A61P 31/18 - Antivirals for RNA viruses for HIV

Abstract

The present invention relates to a naked eye detection method for SARS-CoV-2 RdRp mutations. In the present invention, a colorimetric detection method using the CRISPR-Cas12a system was developed, allowing for easy diagnosis of SARS-CoV-2 RNA using the naked eye. Notably, the detection method according to the present invention is characterized by the ability to specifically and sensitively identify different mutations of SARS-CoV-2.

IPC Classes  ?

• C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
• C12Q 1/6816 - Hybridisation assays characterised by the detection means
• C12Q 1/6844 - Nucleic acid amplification reactions

Abstract

The present invention relates to: a fluorescent probe compound represented by chemical formula 1 or chemical formula 2; and a composite comprising bioceramics, and a fluorescent probe compound represented by chemical formula 1 and/or a fluorescent probe compound represented by chemical formula 2, which are bound to the bioceramics.

IPC Classes  ?

• C09K 11/06 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing organic luminescent materials
• A61K 49/00 - Preparations for testing in vivo
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances

Abstract

The present invention relates to a method for producing a dimeric stilbene using a plant callus culture solution. More specifically, the present invention relates to a method for producing a dimeric stilbene using a plant callus culture solution and a composition for dimeric stilbene production, which contains a plant callus culture solution as an active ingredient.

IPC Classes  ?

• C12P 17/04 - Oxygen as only ring hetero atoms containing a five-membered hetero ring, e.g. griseofulvin
• A01H 4/00 - Plant reproduction by tissue culture techniques

Abstract

The present disclosure provides a compound of a chemical structure having the ability of inhibiting or disintegrating an androgen receptor (AR), or a pharmaceutically acceptable salt of the compound. The present disclosure also provides a composition comprising such a compound or a pharmaceutically acceptable salt thereof. The present disclosure provides a pharmaceutical use of a compound according to the present disclosure, a salt thereof, and a composition comprising same for the treatment or prevention of AR-related diseases. The present disclosure also provides a method for treating or preventing AR-related diseases, comprising administering to a subject in need of treatment an effective amount of a compound according to the present disclosure, a salt thereof, or a composition comprising same.

IPC Classes  ?

• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 295/155 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
• C07D 211/26 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms

Abstract

The present disclosure relates to a JAK3 gene-mutated severe combined immunodeficiency animal model and a method of constructing the same. In the JAK3 gene-mutated severe combined immunodeficiency animal model of the present disclosure, the JAK3 gene is specifically deficient, the expression of cytokines is regulated by controlling the number and activity of macrophages, and the thymus, lymphocytes, and Peyer's patches, which are observed in conventional severe combined immunodeficiency animal models, particularly mini-pigs, are completely lacking. In addition, the animal model of the present disclosure can be used as a treatment model for JAK3 SCID patients, as similar phenotypes are observed in patients with human severe combined immunodeficiency caused by a JAK3 gene mutation, and can be used for artificial blood development or xenotransplantation.

IPC Classes  ?

• A01K 67/027 - New or modified breeds of vertebrates
• C12N 9/22 - Ribonucleases
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 15/90 - Stable introduction of foreign DNA into chromosome

Abstract

The present invention relates to a technology for analyzing and detecting/diagnosing a target nucleic acid. When the detection system according to the present invention is used, effective real-time detection or diagnosis efficiency can be obtained while problems such as noise are minimized. In particular, since, by using a house-keeping gene according to a method of use, the expression difference of the target nucleic acid can be corrected, and direct real-time target nucleic acid detection is possible, it can be effectively used for detecting various nucleic acids and diagnosing various diseases thereby.

IPC Classes  ?

• C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay

Abstract

The present invention relates to an enzyme for producing hydroxy derivatives of polyunsaturated fatty acids, a method for producing hydroxy derivatives of polyunsaturated fatty acids using the same, and an SPMs complex composition containing the hydroxy derivatives of polyunsaturated fatty acids. The present invention relates to an enzyme for producing hydroxy derivatives of polyunsaturated fatty acids, a method for producing hydroxy derivatives of polyunsaturated fatty acids using the same, and an SPMs complex composition containing the hydroxy derivatives of polyunsaturated fatty acids. The enzyme may produce hydroxy derivatives of polyunsaturated fatty acids in a single reaction, and thus may be very usefully used for in vitro production. In addition, the SPMs complex composition containing the hydroxy derivatives of polyunsaturated fatty acids promotes collagen production, inhibits the production of NO and expression of TNF-α and IL-6, increases the expression of filaggrin and loricrin, and thus may be usefully used for preventing or alleviating skin aging or wrinkles, strengthening skin barrier, or preventing, alleviating or treating skin diseases comprising atopic dermatitis.

IPC Classes  ?

• A61K 8/365 - Hydroxycarboxylic acidsKetocarboxylic acids
• A61Q 19/08 - Anti-ageing preparations
• C12P 7/6432 - Eicosapentaenoic acids [EPA]
• C12P 7/6434 - Docosahexenoic acids [DHA]
• C12N 9/02 - Oxidoreductases (1.), e.g. luciferase

Abstract

The present invention relates to a novel cinnamamide derivative and a use thereof in preventing or treating cancer.

IPC Classes  ?

• C07C 235/80 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms having carbon atoms of carboxamide groups and keto groups bound to the same carbon atom, e.g. acetoacetamides
• C07D 213/30 - Oxygen atoms
• A61P 35/00 - Antineoplastic agents
• A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
• A61K 31/4409 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

SYT11SYT11 gene. Also provided in the present invention is a method for providing information necessary for the diagnosis of diffuse type gastric cancer or for determining a therapeutic strategy for diffuse type gastric cancer.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The present invention relates to a novel strain, a lysate thereof, a culture medium, an extract of the culture medium, and anti-inflammatory uses thereof. A strain and a culture medium derived therefrom, according to one aspect, can be effectively used in the prevention, alleviation, or treatment of inflammation-related conditions.

IPC Classes  ?

• C12N 1/20 - BacteriaCulture media therefor
• A61K 35/74 - Bacteria
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• C12R 1/01 - Bacteria or actinomycetales

Abstract

The present invention relates to a method for producing diacid from plastic wastes, and provides a method for biosynthesizing diacid from plastic wastes, the method comprising a step for fermenting plastic pyrolysis oil or a processed product thereof with a genetically recombined transformant, and thus has the advantages in that diacid can be biologically produced from plastic pyrolysis oil, productivity can be improved by distilling and hydrogenating the plastic pyrolysis oil, and high value-added diacid can be biologically produced and recycled from plastic wastes.

IPC Classes  ?

• C12N 15/81 - Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
• C12N 15/52 - Genes encoding for enzymes or proenzymes
• C12P 7/44 - Polycarboxylic acids
• C08J 11/10 - Recovery or working-up of waste materials of polymers by chemically breaking down the molecular chains of polymers or breaking of crosslinks, e.g. devulcanisation

Abstract

The present invention relates to a phenylpropene derivative, and a pharmaceutical composition for the prevention or treatment of cancer, comprising the phenylpropene derivative as an active ingredient. The phenylpropene derivative disclosed in the present specification was confirmed to have an ACC inhibitory activity involved in the inhibition mechanism of tumor proliferation and metastasis.

IPC Classes  ?

• C07C 311/37 - Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
• C07C 211/28 - Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by unsaturated carbon chains
• C07C 211/29 - Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
• C07C 215/48 - Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
• C07C 217/56 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
• C07C 317/32 - SulfonesSulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
• C07C 219/32 - Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings and esterified hydroxy groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
• C07C 229/38 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to acyclic carbon atoms and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
• C07D 317/58 - Radicals substituted by nitrogen atoms
• C07D 295/033 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings

Abstract

The present invention relates a bicycle derivative and a pharmaceutical composition comprising same as an active ingredient for the prevention or treatment of cancer. Found to have ACC inhibitory activity involved in the inhibitory mechanism against tumor proliferation and metastasis, the bicycle derivative disclosed in the description is expected to be useful for preventing or treating cancer.

IPC Classes  ?

• C07C 215/48 - Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
• C07C 235/66 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings being part of condensed ring systems and singly-bound oxygen atoms, bound to the same carbon skeleton
• C07C 219/28 - Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton having amino groups bound to acyclic carbon atoms of the carbon skeleton
• C07C 229/38 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to acyclic carbon atoms and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
• C07D 213/61 - Halogen atoms or nitro radicals
• C07D 231/56 - BenzopyrazolesHydrogenated benzopyrazoles
• C07D 239/80 - Oxygen atoms
• C07D 215/54 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
• C07D 239/72 - QuinazolinesHydrogenated quinazolines
• C07D 241/42 - Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring

Abstract

The present invention relates to a transgenic zebrafish animal model for amyotrophic lateral sclerosis that is induced to overexpress the hFUS(R521C) gene, a construction method therefor, and a method for screening a drug for amyotrophic lateral sclerosis, using same. The animal model construction method of the present invention utilizes a binary expression system, thereby allowing for the stable production of uniform animal models at a large scale. The disease is rapidly induced in the animal models constructed by the method of the present invention and thus the animal models can be advantageously used in amyotrophic lateral sclerosis research including drug screening, etc.

IPC Classes  ?

• A01K 67/027 - New or modified breeds of vertebrates
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
• C12Q 1/6897 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters

Abstract

The present invention pertains to a nanoparticle delivery vehicle designed to bind Cas protein and guide RNA, a nano-complex containing the bound Cas protein and guide RNA, and a gene editing method using same. The use of the nano-complex of the present invention allows for stable and effective delivery of the guide RNA and the Cas protein at the same time into the target cells.

IPC Classes  ?

• C12N 15/87 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 9/22 - Ribonucleases
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12N 15/115 - Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith
• B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

155alkylenediamine in a basic solvent; fluorescent nanoparticles which are polymers of dopamine or dopamine analogs; an imaging composition which comprises the fluorescent nanoparticles of the present invention and can image a plurality of areas; and a hydrogel comprising the fluorescent nanoparticles of the present invention, PVA and water.

IPC Classes  ?

• A61K 49/00 - Preparations for testing in vivo
• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61K 9/06 - OintmentsBases therefor
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers

Abstract

The present invention relates to a system and a method for increasing gene editing efficiency of microalgae by using autolysin. The autolysin and NLS-introduced Cas protein according to one aspect have remarkably improved gene editing efficiency and thus can ultimately improve the production efficiency of gene-edited algae.

IPC Classes  ?

• C12N 15/79 - Vectors or expression systems specially adapted for eukaryotic hosts
• C12N 9/14 - Hydrolases (3.)
• C12N 15/87 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12N 9/22 - Ribonucleases

Abstract

The present invention relates to a pharmaceutical composition for preventing or treating obesity or diabetes, and to a food composition and feed composition for preventing or alleviating obesity or diabetes, comprising as an active ingredient, an Acanthopanax extract, a garcinia cambogia extract, or compounds isolated therefrom. The composition has synergistic antidiabetic and antiobesity activity compared to that of using only an Acanthopanax extract, a garcinia cambogia extract, or compounds isolated therefrom. Therefore, it is possible to reduce the possibility of any side effects that may be caused by an overdose of or long-term administration of the garcinia cambogia extract and a substance isolated therefrom, and thus the composition can be very effectively utilized in the development of a therapeutic agent for diabetes or obesity.

IPC Classes  ?

• A61K 36/258 - Panax (ginseng)
• A61K 31/585 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
• A61K 36/38 - Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
• A61K 31/194 - Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
• A61P 3/08 - Drugs for disorders of the metabolism for glucose homeostasis
• A61P 3/04 - AnorexiantsAntiobesity agents

Abstract

The present invention relates to a novel peptide comprising the sequence of the following general formula 1 or 2, and anti-inflammatory and regenerative uses thereof. [general formula 1] X-Gly-Ala-Tyr [general formula 2] Ala-X-Ser

IPC Classes  ?

• C07K 5/103 - Tetrapeptides the side chain of the first amino acid being acyclic, e.g. Gly, Ala
• C07K 5/11 - Tetrapeptides the side chain of the first amino acid containing more amino groups than carboxyl groups, or derivatives thereof, e.g. Lys, Arg
• C07K 5/083 - Tripeptides the side chain of the first amino acid being acyclic, e.g. Gly, Ala
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A23L 33/18 - PeptidesProtein hydrolysates
• A61K 8/64 - ProteinsPeptidesDerivatives or degradation products thereof
• A61Q 19/00 - Preparations for care of the skin

Abstract

Disclosed are a vector comprising a first expression cassette comprising a DmpR ribosomal binding site as a transcriptional regulator and a promoter operably linked thereto; and a second expression cassette comprising a sequence encoding a target polypeptide, a ribosomal binding site, and a Po promoter operably linked thereto, and a methanotroph transformed by the vector.

IPC Classes  ?

• C12N 15/74 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
• C12N 1/20 - BacteriaCulture media therefor

Abstract

Helicobacter pyloriHelicobacter pylori; and a pharmaceutical composition for the prevention or treatment of gastric mucosal damage-related diseases, comprising a novel active ingredient discovered through this method. The present invention also provides a platform for screening for a therapeutic agent for gastric mucosal damage-related diseases caused by Helicobacter pylori, and a platform for screening for an ingredient that inhibits the gastric adherence of Helicobacter pylori.

IPC Classes  ?

• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof
• A61P 31/04 - Antibacterial agents
• A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• A61P 35/00 - Antineoplastic agents
• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

The present invention relates to a composition for diagnosing infectious diseases, comprising an agent for measuring the expression level of sterol regulatory element-binding protein 2 (SREBP2) and, more specifically, to a composition for diagnosing infectious diseases or diagnosing the severity thereof, the composition comprising an agent for measuring the expression level of sterol regulatory element-binding protein 2 (SREBP2) or a C-terminal peptide thereof.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

The present invention relates to a novel Lactobacillus reuteri DS0384 strain and the use of thereof.

IPC Classes  ?

• C12N 1/20 - BacteriaCulture media therefor
• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system

Abstract

The present disclosure provides a reagent composition for detecting illicit drugs, the composition comprising: a diacetylene derivative compound represented by chemical formula 1; and at least one compound selected from among gabazine (SR-95531), an amine group-linked diacetylene derivative represented by chemical formula 2-1, and a gabazine-linked diacetylene derivative represented by chemical formula 2-2. The present disclosure provides a reagent composition for detecting illicit drugs, the composition comprising: a diacetylene derivative compound represented by chemical formula 1; and at least one compound selected from among gabazine (SR-95531), an amine group-linked diacetylene derivative represented by chemical formula 2-1, and a gabazine-linked diacetylene derivative represented by chemical formula 2-2. The present disclosure provides a reagent composition for detecting illicit drugs, the composition comprising: a diacetylene derivative compound represented by chemical formula 1; and at least one compound selected from among gabazine (SR-95531), an amine group-linked diacetylene derivative represented by chemical formula 2-1, and a gabazine-linked diacetylene derivative represented by chemical formula 2-2. The present disclosure provides a reagent composition for detecting illicit drugs, the composition comprising: a diacetylene derivative compound represented by chemical formula 1; and at least one compound selected from among gabazine (SR-95531), an amine group-linked diacetylene derivative represented by chemical formula 2-1, and a gabazine-linked diacetylene derivative represented by chemical formula 2-2.

IPC Classes  ?

• G01N 33/94 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving narcotics
• C08L 49/00 - Compositions of homopolymers or copolymers of compounds having one or more carbon-to-carbon triple bondsCompositions of derivatives of such polymers
• C07D 237/04 - Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
• G01N 21/78 - Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a change of colour

Abstract

The disclosure relates to nanopore-based technology for screening of drugs against target RNA. According to the screening method of the disclosure, drugs targeting RNA can be efficiently screened even with a very small amount sample of picomolar concentration. The discovered drugs targeting RNA can be used in the treatment of diseases associated with RNAs.

IPC Classes  ?

• G01N 33/487 - Physical analysis of biological material of liquid biological material
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The present invention relates to four types of Gram-positive bacteria (Brevibacterium frigoritolerans (HRS1, KCTC 14301BP), Bacillus niacini (HRS2, KCTC 14302BP), Solibacillus silvestris (HRS3, KCTC 14303BP), and Bacillus luciferensis (HRS4, KCTC 14304BP) strains), which increase resistance of plants against plant pathogens and to a composition of a biocontrol agent by using same and, more specifically, to a microbial fertilizer having a control effect against microbial diseases such as bacterial wilt occurring in crops (tomatoes, peppers, etc.), and against pests such as aphids by using the strains alone or a mixture thereof.

IPC Classes  ?

• A01N 63/20 - BacteriaSubstances produced thereby or obtained therefrom
• A01N 63/22 - Bacillus
• A01P 1/00 - DisinfectantsAntimicrobial compounds or mixtures thereof
• A01P 7/04 - Insecticides

Abstract

The present disclosure relates to a pharmaceutical composition for preventing or treating an inflammatory disease, comprising a benzofuran-based N-acylhydrazone compound, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof. The benzofuran-based N-acylhydrazone compound according to the present disclosure inhibits the activity of NF-κB, which is a major signal transmitter in the inflammatory response, thereby disrupting the initial pathway and process of the biological inflammatory response system and inhibiting inflammatory immune cells and inflammatory cytokines, and thus can prevent and treat various pathological diseases caused by the inflammatory response.

IPC Classes  ?

• A61K 31/404 - Indoles, e.g. pindolol
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

The present application relates to a pharmaceutical composition for preventing or treating cancer comprising an NMUR2 expression inhibitor or an NMUR2 activity inhibitor as an active ingredient. A pharmaceutical composition of the present invention comprising an NMUR2 inhibitor according to the present invention as an active ingredient is advantageous in that the composition can be used as an alternative anticancer agent in cases where unresponsiveness or resistance to conventional anticancer agents is exhibited.

IPC Classes  ?

• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
• A61P 35/00 - Antineoplastic agents
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

The present invention relates to an insecticide composition comprising a novel emamectin glycoside and, more particularly, to: an insecticide composition comprising a novel emamectin glycoside with a remarkably increased Bursaphelenchus xylophilus control ability and water solubility; and a pest control method using same.

IPC Classes  ?

• C07H 19/01 - Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radicalNucleosidesMononucleotidesAnhydro derivatives thereof sharing oxygen
• A01N 43/32 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atom with two or more hetero atoms six-membered rings
• A01N 43/90 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system

Abstract

The present invention relates to: a composition for preventing, alleviating or treating dry eye syndrome or meibomian gland dysfunction; and the like, and was completed by identifying the excellent effects of treating dry eye syndrome with 1,5-O-dicaffeoylquinic acid and improving meibomian gland function. 1,5-O-dicaffeoylquinic acid, a key component of the present invention, reduces corneal epithelial loss, increases the amount of tear secretion, inhibits inflammation of the lacrimal and meibomian glands, increases the area of the meibomian gland, increases the survival rate of corneal epithelial cells in a hyperosmotic environment, and can inhibit cell death. Therefore, the composition according to the present invention can effectively treat dry eye syndrome caused by environmental stress or various diseases and improve meibomian gland function, and thus is expected to be used as a therapeutic agent for various eye diseases.

IPC Classes  ?

• A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
• A61P 27/02 - Ophthalmic agents
• A61P 27/04 - Artificial tearsIrrigation solutions
• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

The present invention relates to a method for biosynthesizing N-carbamyl-L-glutamic acid and a novel use thereof for the prevention or treatment of inflammatory diseases. The invention also relates to a composition for the prevention, amelioration or treatment of inflammatory bowel disease, which contains N-carbamyl-L-glutamic acid as an active ingredient, thereby minimizing the side effects of existing treatments for inflammatory bowel disease and securing stability.

IPC Classes  ?

• C12P 13/14 - Glutamic acidGlutamine
• C12N 1/20 - BacteriaCulture media therefor
• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A23L 33/175 - Amino acids
• A23K 20/142 - Amino acidsDerivatives thereof

Abstract

The present disclosure relates to TM4SF5-specific humanized antibodies and uses thereof.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression

Abstract

The present invention relates to a pharmaceutical composition for preventing or treating colorectal cancer comprising an EDNRA inhibitor as an active ingredient. Specifically, it was confirmed that the proliferation of colorectal cancer cells decreased and apoptosis increased when EDNRA expression was inhibited, and thus, inhibition of EDNRA can be a treatment mechanism for colorectal cancer, and it was confirmed that APY29 and CGP60474 were screened for EDNRA inhibitor drugs and treating the colorectal cancer cells with APY29 and CGP60474 caused apoptosis. In addition, it was confirmed that when APY29 and CGP60474 compounds selected as EDNRA inhibitors were administered simultaneously with irinotecan, topotecan, or daunorubicin, which are cytotoxic anti-cancer drugs widely used in the treatment of colorectal cancer, the cancer cell apoptosis effect increased, and thus, the cancer treatment effect could be improved via co-administration with anticancer drugs.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61P 35/00 - Antineoplastic agents
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The present invention relates to: a method for two-dimensionally culturing an intestinal stem cell aggregate in a medium having a clear chemical composition; and a use thereof, and relates to: a method for differentiating the intestinal stem cell aggregate into 2.5-dimensional intestinal epithelial cells; and a use thereof.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues

Abstract

The present invention provides a target RNA detection method based on a dCas9/gRNA complex. A target RNA detection method according to the present invention can detect target RNA with the naked eye and without separate gene isolation and amplification steps, and, in particular, can rapidly and accurately detect target RNA through excellent target specificity and rapidity, and thus can exhibit excellent effects on the detection of various pathogens and/or viruses.

IPC Classes  ?

• C12Q 1/6834 - Enzymatic or biochemical coupling of nucleic acids to a solid phase
• C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage

Abstract

The present invention relates to a graphene channel including a graphene film and a graphene nanoparticle film and to a biosensor and a wearable device, including same, and it is possible to amplify a pulse signal, to directly measure pulse, and to measure not only pulse rate and strength but also arrhythmia.

IPC Classes  ?

• A61B 5/024 - Measuring pulse rate or heart rate
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• C01B 32/186 - Preparation by chemical vapour deposition [CVD]
• H01B 1/04 - Conductors or conductive bodies characterised by the conductive materialsSelection of materials as conductors mainly consisting of carbon-silicon compounds, carbon, or silicon
• H01B 5/14 - Non-insulated conductors or conductive bodies characterised by their form comprising conductive layers or films on insulating-supports